Baidu
map

Lab Invest:Fezf2功能的丧失能够促进膀胱癌恶性发展

2018-06-29 AlexYang MedSci原创

前脑胚胎锌指蛋白2(Fezf2)是一个进化保守的锌指结构转录抑制子。之前报道它是一个肿瘤抑制因子;然而,Fezf2在膀胱癌中的作用或者相关的机制还没有很好的研究。最近,有研究人员展示了与临近的非肿瘤组织和正常泌尿道上皮细胞相比,Fezf2的表达在膀胱癌组织和细胞系中下调。研究人员同样在196名膀胱癌患者中,回顾性的分析了Fezf2与各种临床病理特性的相关性。研究发现Fezf2的低表达量与更大的肿瘤

前脑胚胎锌指蛋白2(Fezf2)是一个进化保守的锌指结构转录抑制子。之前报道它是一个肿瘤抑制因子;然而,Fezf2在膀胱癌中的作用或者相关的机制还没有很好的研究。

最近,有研究人员展示了与临近的非肿瘤组织和正常泌尿道上皮细胞相比,Fezf2的表达在膀胱癌组织和细胞系中下调。研究人员同样在196名膀胱癌患者中,回顾性的分析了Fezf2与各种临床病理特性的相关性。研究发现Fezf2的低表达量与更大的肿瘤尺寸、更晚的肿瘤阶段和临床不良预后有关联。更多的是,研究人员还发现了Fezf2的过表达能够显著的抑制膀胱癌细胞的增殖、生长、迁移和侵入能力,并且能够减弱血管生成作用,然而当敲除Fezf2时具有与上述相反的作用。

最后,研究人员指出,Fezf2能够通过激活 NF-κB信号通路来抑制膀胱癌细胞恶性发展。他们的这些发现表明了Fezf2是一个有前景的预后生物标记,并且为膀胱癌的恶性发展提供了一个假定的机制。

原始出处:

Zhaohui Chen, Lijie Zhou, Xuehan Liu et al. Loss of Fezf2 promotes malignant progression of bladder cancer by regulating the NF-κB signaling pathway. Lab Invest. 20 June 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051171, encodeId=ddcd20511e164, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Oct 24 15:46:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328423, encodeId=b63f3284232b, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Jul 01 10:11:27 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328151, encodeId=3da332815143, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 30 08:23:51 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328036, encodeId=5ec232803616, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Jun 29 23:28:50 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328028, encodeId=ba5f32802891, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 29 22:56:09 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051171, encodeId=ddcd20511e164, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Oct 24 15:46:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328423, encodeId=b63f3284232b, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Jul 01 10:11:27 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328151, encodeId=3da332815143, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 30 08:23:51 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328036, encodeId=5ec232803616, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Jun 29 23:28:50 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328028, encodeId=ba5f32802891, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 29 22:56:09 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
    2018-07-01 一个字-牛

    学习了谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2051171, encodeId=ddcd20511e164, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Oct 24 15:46:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328423, encodeId=b63f3284232b, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Jul 01 10:11:27 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328151, encodeId=3da332815143, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 30 08:23:51 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328036, encodeId=5ec232803616, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Jun 29 23:28:50 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328028, encodeId=ba5f32802891, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 29 22:56:09 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
    2018-06-30 kafei

    学习了谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2051171, encodeId=ddcd20511e164, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Oct 24 15:46:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328423, encodeId=b63f3284232b, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Jul 01 10:11:27 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328151, encodeId=3da332815143, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 30 08:23:51 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328036, encodeId=5ec232803616, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Jun 29 23:28:50 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328028, encodeId=ba5f32802891, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 29 22:56:09 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
    2018-06-29 明月清辉

    谢谢分享.学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2051171, encodeId=ddcd20511e164, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Oct 24 15:46:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328423, encodeId=b63f3284232b, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Jul 01 10:11:27 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328151, encodeId=3da332815143, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 30 08:23:51 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328036, encodeId=5ec232803616, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Jun 29 23:28:50 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328028, encodeId=ba5f32802891, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 29 22:56:09 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
    2018-06-29 1e0f8808m18(暂无匿称)

    学习了.谢谢分享!

    0

相关资讯

Sci Rep:通过尿液代谢组学分析对膀胱癌复发的监控研究

非肌肉侵入性膀胱癌(NMIBC)是世界范围上最为常见的的恶性肿瘤之一。NMIBC主要通过膀胱肿瘤的通过尿道的切除(TURBT)和膀胱内疗法进行治疗,并且在实体瘤中具有最高的复发率。因此,需要基于重复的膀胱镜检查和尿细胞学检查进行终生的监控,但是上述两种方法均具有缺陷,包括了敏感性和特异性的缺乏,侵入性和护理费用。最近,有研究人员进行了一个调查性的临床研究来检查NMBIC患者在TURBT前后以及在随

JBC:研究发现新膀胱癌转移机制

5 月 4 日,国际学术期刊 Journal of Biochemical Biology 在线发表了南京大学模式动物研究所教授严俊,中国科学院上海药物研究所研究员黄锐敏、周虎和南京大学附属鼓楼医院泌尿外科系教授郭宏骞的合作研究成果 Wnt7a activates canonical Wnt signaling, promotes bladder cancer cell invasion, and

Brit J Cancer:英国膀胱癌患者治疗后健康相关生活质量研究

目前,在膀胱癌治疗后生活质量方面的情况了解还很少。这种常见的癌症所使用的治疗方法能够影响泌尿、性功能和肠道功能。最近,有研究人员为了探明上述情况,进行了相关的调查研究。研究总共有673名患者响应;包括了500名(74%)男性,且539名(80%)具有共存的条件。大多数的响应者接受了内窥镜治疗(60%),然而92名(14%)和99名(15%)患者分别接受了根治性膀胱切除术或者放射治疗。调查问卷完成比

Sci Rep:在肌肉侵入性膀胱癌中,膀胱部分切除术后的肿瘤结果、生活质量结果和并发症结果研究

最近,有研究人员为了评估患有肌肉侵入性膀胱癌(MIBC)患者经历膀胱部分切除术(PC)后的肿瘤结果、相关的并发症和术后健康相关的生活质量(HR-QoL),他们进行了相关的研究,研究包括了27名经历了cT2 MIBC开放PC手术的患者。研究人员利用一个简单的Cox's比例风险回归模型来评估一些潜在的预后因素与生存的关系,利用EORTC QLQ-C30调查问卷3.0版本评估了术后HR-QoL。研究发现

ASCO速递:PD-L1表达可预测膀胱癌免疫治疗疗效

在经PD-L1抑制剂durvalumab治疗的晚期UC队列中,经回顾性模型分析发现,采用肿瘤细胞(TC)或免疫细胞(IC)上的PD-L1表达≥25%的算法,可筛选出获得最佳临床结果(包括ORR和OS)的患者!(见下表)

NCCN临床实践指南:膀胱癌(2018.V4)

2018年5月,美国国家综合癌症网络(NCCN)发布了膀胱癌指南2018年第4版,指南主要内容包括: 指南更新摘要 膀胱癌 临床表现和初始评估 非侵袭性或Tis,初步评估/手术治疗 肌层侵袭或转移,初步评估/手术治疗,额外检查 膀胱/移行细胞癌影像学检查 手术治疗原则

Baidu
map
Baidu
map
Baidu
map